On August 19, Regeneron Pharmaceuticals rose 3.44% in regular trading, trading at $842.53/share, with turnover of $102 million. The stock benefited from a significant analyst upgrade and broad biotech sector momentum.

Leerink Partners raised its target price on Regeneron from $641 to $824 on August 17, representing a 28.5% increase, while maintaining its market perform rating. Bernstein had also previously lifted its target modestly to $756. The average analyst target price stands at $838.80, with a consensus overweight rating according to FactSet.

The broader biotechnology sector provided additional tailwinds, with Moderna surging over 119%, BioNTech rising nearly 20%, Amgen gaining 3.78%, and Gilead Sciences climbing 3.76% during the session. This sector-wide strength amplified the positive sentiment from the analyst upgrades.

Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines across multiple therapeutic areas including eye diseases, allergic and inflammatory conditions, oncology, and rare diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)